AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues
Authors: Vaidyanathan, G Shankar, S Zalutsky, MR
Citation: G. Vaidyanathan et al., Synthesis of ring- and side-chain-substituted m-iodobenzylguanidine analogues, BIOCONJ CHE, 12(5), 2001, pp. 786-797
Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues
Authors: Vaidyanathan, G Shankar, S Affleck, DJ Welsh, PC Slade, SK Zalutsky, MR
Citation: G. Vaidyanathan et al., Biological evaluation of ring- and side-chain-substituted m-iodobenzylguanidine analogues, BIOCONJ CHE, 12(5), 2001, pp. 798-806
A polar substituent containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[I-131]iodobenzbate ([I-131]SGMIB)
Authors: Vaidyanathan, G Affleck, DJ Li, J Welsh, P Zalutsky, MR
Citation: G. Vaidyanathan et al., A polar substituent containing acylation agent for the radioiodination of internalizing monoclonal antibodies: N-succinimidyl 4-guanidinomethyl-3-[I-131]iodobenzbate ([I-131]SGMIB), BIOCONJ CHE, 12(3), 2001, pp. 428-438
Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-Iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR
Authors: Foulon, CF Welsh, PC Bigner, DD Zalutsky, MR
Citation: Cf. Foulon et al., Positively charged templates for labeling internalizing antibodies: comparison of N-succinimidyl 5-Iodo-3-pyridinecarboxylate and the D-amino acid peptide KRYRR, NUCL MED BI, 28(7), 2001, pp. 769-777
High-level production of alpha-particle-emitting At-211 and preparation ofAt-211-Labeled antibodies for clinical use
Authors: Zalutsky, MR Zhao, XG Alston, KL Bigner, D
Citation: Mr. Zalutsky et al., High-level production of alpha-particle-emitting At-211 and preparation ofAt-211-Labeled antibodies for clinical use, J NUCL MED, 42(10), 2001, pp. 1508-1515
Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia
Authors: Meyer, DE Kong, GA Dewhirst, MW Zalutsky, MR Chilkoti, A
Citation: De. Meyer et al., Targeting a genetically engineered elastin-like polypeptide to solid tumors by local hyperthermia, CANCER RES, 61(4), 2001, pp. 1548-1554
Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study
Authors: Cokgor, I Akabani, G Friedman, HS Friedman, AH Zalutsky, MR Zehngebot, LM Provenzale, JM Guy, CD Wikstrand, CJ Bigner, DD
Citation: I. Cokgor et al., Long term response in a patient with neoplastic meningitis secondary to melanoma treated with I-131-radiolabeled antichondroitin proteoglycan sulfateMel-14 F(ab ')(2) - A case study, CANCER, 91(9), 2001, pp. 1809-1813
Radiolabeled antibodies for therapy of brain tumors
Authors: Wikstrand, CJ Zalutsky, MR Bigner, DD
Citation: Cj. Wikstrand et al., Radiolabeled antibodies for therapy of brain tumors, BRAIN TUMOR IMMUNOTHERAPY, 2001, pp. 205-229
Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy
Authors: Zalutsky, MR Vaidyanathan, G
Citation: Mr. Zalutsky et G. Vaidyanathan, Astatine-211-labeled radiotherapeutics: An emerging approach to targeted alpha-particle radiotherapy, CUR PHARM D, 6(14), 2000, pp. 1433-1455
Synergistic interaction between anti-p185(HER-2) ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2
Authors: Xu, FJ Leadon, SA Yu, YH Boyer, CM O'Briant, K Ward, K McWatters, A Zhao, XG Bae, DS DeSombre, K Zalutsky, MR Bast, RC
Citation: Fj. Xu et al., Synergistic interaction between anti-p185(HER-2) ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2, CLIN CANC R, 6(8), 2000, pp. 3334-3341
Radiolabeled guanine derivatives for the in vivo mapping of O-6-alkylguanine-DNA alkyltransferase: 6-(4-[F-18]fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[I-131]iodo-benzyloxy)-9H-purin-2-ylamine
Authors: Vaidyanathan, G Affleck, DJ Cavazos, CM Johnson, SP Shankar, S Friedman, HS Colvin, MO Zalutsky, MR
Citation: G. Vaidyanathan et al., Radiolabeled guanine derivatives for the in vivo mapping of O-6-alkylguanine-DNA alkyltransferase: 6-(4-[F-18]fluoro-benzyloxy)-9H-purin-2-ylamine and 6-(3-[I-131]iodo-benzyloxy)-9H-purin-2-ylamine, BIOCONJ CHE, 11(6), 2000, pp. 868-875
Radioiodination and astatination of octreotide by conjugation labeling
Authors: Vaidyanathan, G Affleck, D Welsh, P Srinavasan, A Schmidt, M Zalutsky, MR
Citation: G. Vaidyanathan et al., Radioiodination and astatination of octreotide by conjugation labeling, NUCL MED BI, 27(4), 2000, pp. 329-337
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry
Authors: Aurlien, E Larsen, RH Akabani, G Olsen, DR Zalutsky, MR Bruland, OS
Citation: E. Aurlien et al., Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry, INT J RAD B, 76(8), 2000, pp. 1129-1141
Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas
Authors: Cokgor, I Akabani, G Kuan, CT Friedman, HS Friedman, AH Coleman, RE McLendon, RE Bigner, SH Zhao, XG Garcia-Turner, AM Pegram, CN Wikstrand, CJ Shafman, TD Herndon, JE Provenzale, JM Zalutsky, MR Bigner, DD
Citation: I. Cokgor et al., Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas, J CL ONCOL, 18(22), 2000, pp. 3862-3872
Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy
Authors: Akabani, G Cokgor, I Coleman, RE Trotter, DG Wong, TZ Friedman, HS Friedman, AH Garcia-Turner, A Herndon, JE DeLong, D McLendon, RE Zhao, XG Pegram, CN Provenzale, JM Bigner, DD Zalutsky, MR
Citation: G. Akabani et al., Dosimetry and dose-response relationships in newly diagnosed patients withmalignant gliomas treated with iodine-131-labeled anti-tenascin monoclonalantibody 81C6 therapy, INT J RAD O, 46(4), 2000, pp. 947-958
Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFv
Authors: Kuan, CT Wikstrand, CJ Archer, G Beers, R Pastan, I Zalutsky, MR Bigner, DD
Citation: Ct. Kuan et al., Increased binding affinity enhances targeting of glioma xenografts by EGFRVIII-specific scFv, INT J CANC, 88(6), 2000, pp. 962-969
Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody
Authors: Foulon, CF Reist, CJ Bigner, DD Zalutsky, MR
Citation: Cf. Foulon et al., Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody, CANCER RES, 60(16), 2000, pp. 4453-4460
Radiohalogens for radioimmunotherapy
Authors: Zalutsky, MR
Citation: Mr. Zalutsky, Radiohalogens for radioimmunotherapy, RADIOIMMUNOTHERAPY OF CANCER, 2000, pp. 81-106
I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts
Authors: Kuan, CT Reist, CJ Foulon, CF Lorimer, IAJ Archer, G Pegram, CN Pastan, I Zalutsky, MR Bigner, DD
Citation: Ct. Kuan et al., I-125-labeled anti-epidermal growth factor receptor-vIII single-chain Fv exhibits specific and high-level targeting of glioma xenografts, CLIN CANC R, 5(6), 1999, pp. 1539-1549
Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications
Authors: Foulon, CF Bigner, DD Zalutsky, MR
Citation: Cf. Foulon et al., Preparation and characterization of anti-tenascin monoclonal antibody-streptavidin conjugates for pretargeting applications, BIOCONJ CHE, 10(5), 1999, pp. 867-876
Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects oflabeling method on cellular processing and tissue distribution
Authors: Zalutsky, MR Xu, FJ Yu, Y Foulon, CF Zhao, XG Slade, SK Affleck, DJ Bast, RC
Citation: Mr. Zalutsky et al., Radioiodinated antibody targeting of the HER-2/neu oncoprotein: Effects oflabeling method on cellular processing and tissue distribution, NUCL MED BI, 26(7), 1999, pp. 781-790
Synthesis, purification, and in vitro stability of At-211- and I-125-labeled amidobisphosphonates
Authors: Murud, KM Larsen, RH Hoff, P Zalutsky, MR
Citation: Km. Murud et al., Synthesis, purification, and in vitro stability of At-211- and I-125-labeled amidobisphosphonates, NUCL MED BI, 26(4), 1999, pp. 397-403
Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[At-211]astato-3-pyridinecarboxylate
Authors: Reist, CJ Foulon, CF Alston, K Bigner, DD Zalutsky, MR
Citation: Cj. Reist et al., Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[At-211]astato-3-pyridinecarboxylate, NUCL MED BI, 26(4), 1999, pp. 405-411
Radiotoxicity of systemically administered At-211-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis
Authors: McLendon, RE Archer, GE Larsen, RH Akabani, G Bigner, DD Zalutsky, MR
Citation: Re. Mclendon et al., Radiotoxicity of systemically administered At-211-labeled human/mouse chimeric monoclonal antibody: A long-term survival study with histologic analysis, INT J RAD O, 45(2), 1999, pp. 491-499
At-211- and I-131-labeled bisphosphonates with high in vivo stability and bone accumulation
Authors: Larsen, RH Murad, KM Akabani, G Hoff, P Bruland, OS Zalutsky, MR
Citation: Rh. Larsen et al., At-211- and I-131-labeled bisphosphonates with high in vivo stability and bone accumulation, J NUCL MED, 40(7), 1999, pp. 1197-1203
Risultati: 1-25 | 26-26